

Technology Advisory Committee A Interests Register
Semaglutide for managing overweight and obesity [ID3850]

Publication Date: 8 March 2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Michael Holmes	Committee member	Indirect - financial	Dr Holmes is collaborating with Novo Nordisk in an academic collaboration at the University of Oxford. This is in relation to a proteomics dataset which will be used to explore potential therapeutic targets. He has received no personal funding.	N/A	18.01.2022 07.03.2022	N/A	It was agreed that his declaration would not prevent Dr Holmes from participating in discussions on this appraisal.
Sarah le Brocq	Patient expert	Direct financial and direct non-financial	Sarah has taken part in Novo Nordisk internal meetings sharing her experiences of living with obesity with their employees, she is a Disease Experience Expert Panel (DEEP) member for Novo Nordisk and has taken part in a number of lived experience presentations she is also involved in the Liraglutide TA and a Trustee of the	N/A	06.08.2021	N/A	It was agreed that this declaration would not prevent Sarah le Brocq from participating in discussions on this appraisal.

			Association for the Study of Obesity				
Professor Carel le Roux	Clinical expert	Direct financial and direct non-financial	Dr Le Roux has served on the global advisory boards for the below companies and have also received honorariums for speaker events from Novo Nordisk, Boehringer Ingelheim, Herbalife, Johnson & Johnson, GI Dynamics and Keyron. He is a director of the Irish Society for Clinical Nutrition and Metabolism (IrSPEN) and has contributed to patient organisations including the Irish Coalition for People living with Obesity (ICPO). He is the coordinator of a European Union project SOPHIA, interested in reshaping the narrative around obesity as a disease.	N/A	June 2021	N/A	It was agreed that his declarations would not prevent Professor le Roux from providing expert advice to the committee.
Professor John Wilding	Clinical expert	Direct & indirect financial	Professor Wilding has received honoraria / lecture fees from AstraZeneca, Boehringer Ingelheim, Lilly, Napp,	N/A	June 2021	N/A	It was agreed that his declarations would not prevent Professor Wilding from providing

			<p>Novo Nordisk, Mundipharma, Sanofi and Takeda. he has undertaken paid editorial work Springer Nature (Medicine Matters Diabetes website) and has also been paid for lectures / webinars by Medscape. he undertakes consultancy for industry contracted via the University of Liverpool (no personal payment) in relation to obesity and type 2 diabetes. In the last 12 months I have undertaken work for AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Lilly, Napp, Novo Nordisk, Mundipharma, Rhythm Pharmaceuticals, Sanofi, and Saniona. He is a named grantholder (at University of Liverpool) for research grants for clinical trials from AstraZeneca and Novo Nordisk. He is president of the World Obesity Federation, and a member of the</p>				expert advice to the committee.
--	--	--	---	--	--	--	---------------------------------

			Association for the Study of Obesity, Diabetes UK, EASD, ADA and Society for Endocrinology. He is a member of the Rank Prize Funds Nutrition Committee and a member of the steering committee for a tier 3 obesity audit being set up via the Society for Endocrinology via a grant from Novo Nordisk (all unpaid positions).				
Dr Bernard Khoo	Committee member	Direct non-financial professional interest	He has prescribed semaglutide for diabetes and obesity both in NHS practice and privately, he is also married to a metabolic medicine physician who is involved in a Tier 3 NHS obesity clinic and will be prescribing semaglutide according to guidance from NICE.	N/A	15.03.22	N/A	It was agreed that his declarations would not prevent Dr Khoo from participating in discussions on this appraisal.